INT213256

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.59
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2C9) oxidoreductase activity (CYP2C9) endoplasmic reticulum (CYP2C9)
CYP2C9 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 8 47.68 Quite Low
headache 2 5.00 Very Low Very Low Very Low
Serotonin 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Congenital Anomalies 7 86.44 High High
Hemorrhage 7 81.12 Quite High
Nose Bleeds 1 76.52 Quite High
Sleep Disorders 1 71.48 Quite High
Fatigue 1 70.92 Quite High
Pressure And Volume Under Development 4 69.84 Quite High
Pulmonary Hypertension 53 12.16 Low Low
Toxicity 1 8.48 Low Low
Increased Venous Pressure Under Development 4 5.00 Very Low Very Low Very Low
Cv General 4 Under Development 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Due to the effect of sitaxsentan on inhibition of the CYP2C9, an 80% reduction in the warfarin dose for sitaxsentan patients was recommended at baseline for sitaxsentan-treated patients, with adjustment made as needed to maintain international normalized ratio (INR).
Regulation (effect) of Negative_regulation (inhibition) of CYP2C9
1) Confidence 0.05 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994033 Disease Relevance 0.59 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox